Nasdaq Panel denies CERo Therapeutics continued listing; stock to suspend Oct 31

CERO THERAPEUTICS HOLDINGS, INC.

Shares of CERO common stock will be suspended from Nasdaq at open of trading on October 31, 2025.
Company has appealed to Nasdaq Listing and Hearing Review Council; also seeks OTC Markets trading.
$4.75M Series E Preferred financing contingent on Nasdaq listing; funding now uncertain.
Early clinical data for CER-1236 in three AML patients shows rapid cell expansion and no toxicity.
Company reviewing cash resources and financing alternatives; no assurance of funding.

item 3.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.